<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04279379</url>
  </required_header>
  <id_info>
    <org_study_id>TRhos-ENKTCL-2</org_study_id>
    <nct_id>NCT04279379</nct_id>
  </id_info>
  <brief_title>Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma</brief_title>
  <official_title>Combination of Sintilimab and Decitabine for Patients With Relapsed/Refractory or Advanced NK/T-cell Lymphoma : a Single Arm,Open-lable,Phase II Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Tongren Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Tongren Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of Sintilimab in combination
      with decitabine in the treatment of Relapsed/Refractory or advanced NK/T-cell lymphoma
      patients
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous study has confirmed the efficacy of anti-PD-1 antibodies (including pembrolizumab or
      sintilimab). However, the CR rate of PD-1 antibody monotherapy is too low. Previous studies
      have demonstrated that decitabine may activate the T cells and enhance the efficacy of PD-1
      antibodies in Hodgkin Lymphoma. Thus, the investigators aim to evaluate the efficacy and
      safety of sintilimab in combination with decitabine in the treatment of NK/T cell lymphoma.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>treatment with sintilimab and decitabine.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>complete response rate</measure>
    <time_frame>24 weeks ±7 days</time_frame>
    <description>evaluated by PET-CT and MRI, according to Lugano 2014 criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>24 weeks ±7 days</time_frame>
    <description>evaluated by PET-CT and MRI, according to Lugano 2014 criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year progression free survival rate</measure>
    <time_frame>up to 1year after enrollment</time_frame>
    <description>time from date of enrollment to date of disease progression, death of any reason, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year overall survival rate</measure>
    <time_frame>up to 1year after enrollment</time_frame>
    <description>time from date of enrollment to date death of any reason</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Extranodal NK/T-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sintilimab,200mg,ivdrip,day1 Decitabine 10mg d1-5, ivdrip, repeated every 3 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sintilimab</intervention_name>
    <description>200mg d1,ivdrip, repeated every 3 weeks</description>
    <arm_group_label>treatment arm</arm_group_label>
    <other_name>anti-PD-1-antibody</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>10mg d1-5, ivdrip,repeated every 3 weeks</description>
    <arm_group_label>treatment arm</arm_group_label>
    <other_name>hypomethylating agents</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Histopathology and immunohistochemistry confirmed diagnosis of NK/Tcell lymphoma according
        to WHO 2016 criteria.

          -  refractory or relapsed after initial remission, or stage III-IV de novo patients

          -  PET/CT or CT/MRI with at least one objectively evaluable lesion.

          -  General status ECOG score 0-3 points.

          -  The laboratory test within 1 week before enrollment meets the following conditions:
             Blood routine: Hb&gt;80g/L, PLT&gt;50×10e9/L. Liver function: ALT, AST, TBIL ≤2 times the
             upper limit of normal. Renal function: Cr is normal. Cardiac function: LVEF≥50%, ECG
             does not suggest any acute myocardial infarction, arrhythmia or atrioventricular
             conduction above I Blocking.

          -  Sign the informed consent form

        Exclusion Criteria:

        Active infection requires ICU treatment. Concomitant HIV infection or active infection with
        HBV, HCV. Patients who are infected with HBV but not active hepatitis at the same time are
        notexcluded.

        Significant organ dysfunction Pregnant and lactating women. Had a history of autoimmune
        diseases, and disease was active in the last 6 months.

        Those who were known to be allergic to drugs in the study regimen. Patients with other
        tumors who require surgery or chemotherapy within 6 months.

        • Other experimental drugs are being used.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jing-wen Wang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Beijing Tongren Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>LIANG WANG, M.D.</last_name>
    <phone>+8615013009093</phone>
    <email>wangliangtrhos@126.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Tongren Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liang Wang, MD</last_name>
      <phone>+8615001108693</phone>
      <email>wangliangtrhos@126.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>February 19, 2020</study_first_submitted>
  <study_first_submitted_qc>February 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 21, 2020</study_first_posted>
  <last_update_submitted>May 6, 2020</last_update_submitted>
  <last_update_submitted_qc>May 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Tongren Hospital</investigator_affiliation>
    <investigator_full_name>JING-WEN WANG</investigator_full_name>
    <investigator_title>Director of department of hematology</investigator_title>
  </responsible_party>
  <keyword>extranodal NK/T-cell lymphoma</keyword>
  <keyword>PD-1 blockade</keyword>
  <keyword>decitabine</keyword>
  <keyword>sintilimab</keyword>
  <keyword>hypomethylation</keyword>
  <keyword>epigenetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Extranodal NK-T-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Decitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

